A pharmaceutical drug called Spravato is used to treat suicidal adults with major depressive disorder or treatment-resistant depression. It is combined with another antidepressant that is taken orally. Visit a psychiatrist Atlanta to schedule your appointment today.
Is it effective?
Spravato is a ketamine nasal spray that has been approved for individuals with treatment-resistant depression. Clinical studies demonstrate that when combined with an oral antidepressant and administered under the supervision of a healthcare expert in a registered facility, it successfully reduces depressive symptoms. Within the first 24 hours of taking Spravato, there was an improvement. It is not intended for use by youngsters.
Is it FDA-approved?
Spravato was approved by the FDA in 2019 for the treatment of treatment-resistant depression (TRD) and for major depressive disorder (MDD) with suicidal thoughts or actions later in 2020. Its approval is contentious because of its resemblance to ketamine, rapid action, potential side effects such as dissociation and drowsiness, and potential for abuse. Long-term studies are being conducted to evaluate its safety and efficacy. It is given by skilled healthcare experts in certified facilities and must be monitored afterward.
Spravato is licensed by the FDA to treat suicidal thoughts or behaviors in patients suffering from treatment-resistant depression (TRD) or major depressive disorder (MDD). It is not licensed for the treatment of pain, although it may be used for other conditions off-label.
When taken in conjunction with an oral antidepressant, Spravato lowered depression symptoms significantly more than a placebo in a 4-week clinical investigation. The most significant improvement was seen within the first 24 hours after taking Spravato. Spravato continued to minimize depression symptoms in a year-long research, and those who took it were less likely to revert back to severe depression than those on a placebo.
Spravato is an FDA-approved treatment for major depressive disorder (MDD) in individuals who have suicidal thoughts or behaviors. It is taken alongside at least one other oral antidepressant. While clinical studies have shown that Spravato is beneficial in treating MDD with suicidal thoughts or actions, it is not known if it helps prevent suicidal thoughts or behaviors. During treatment, your doctor will monitor and manage these symptoms as needed. The price of Spravato varies, and it is not available for purchase directly from a pharmacy. It will be obtained by your doctor’s office from a specialty pharmacy. Your insurance coverage will determine whether or not it is covered.